- Blackstone Griddle Black Friday & Cyber Monday (2023): Review of Latest Griddle Offers Reported by Deal Tomato
- Woburn Dentistry Provides Comprehensive Perio Procedures From One Convenient Location
- Away Travel Luggage Cyber Monday (2023): Round-up of Latest Offers Published by Deal Stripe
Dr. Davis brings a wealth of experience in drug delivery, diagnostics, and biopharmaceutical development from his time at AstraZeneca and Amgen, where he held multiple roles of increasing responsibility focusing on combination product development, technology strategy, and innovation. He has also provided thought leadership across the industry as a frequent speaker and chair of multiple conferences and as a Subcutaneous Drug Development & Delivery Consortium board member.
Dr. Strapps is an experienced biotech executive who most recently served as Chief Executive Officer of Carver Biosciences, Inc., and currently serves as interim Chief Scientific Officer of Deep Genomics. He has held various roles leading research efforts in oligonucleotide-based therapeutics over the last 20 years at Sirna Therapeutics, Merck & Co., Inc., and Intellia Therapeutics.
More on Boston Chron
- Mayor Wu Announces $1 Million in New Grant Funding to Support the Revitalization of Boston's Restaurant Industry
- Allotex Announces New Investor and Expansion of Production Facilities USA - English USA - English
- Green Office Partner Launches Managed Print Services Program in Canada
- GLCPS Sponsors Two Students to Attend Brown University Leadership Institute
- Vantiva Confirms its Strong Commitment to Diversity, Equity and Inclusion
Commenting on his appointment, Dr. Davis said: "The field of genetic medicines is fascinating, not only for the potential to address the critical needs of patients but also as the next frontier of human medicine... Our ability to rapidly and efficiently design new delivery vehicles has the potential to enable future pharmaceutical partners' pipelines and address previously unreachable biologic targets liberating patients from their genetic disorders."
Liberate Bio was co-founded in 2022 by Drs Michael Mitchell, Stephen Scully, Theresa Reineke, and Nessan Bermingham with a focus on identifying and developing new vehicles to deliver oligonucleotide cargos. With the addition of two experienced leaders in drug delivery technology to its team, Liberate Bio is well positioned to make significant progress towards its goal of providing innovative solutions for genetic medicine treatments.
Filed Under: Business
Latest on Boston Chron
- Unveiling a Secluded Paradise: Beachfront Home on Dog Island, Carrabelle, Florida, Goes to Auction
- ASICS Teams Up with BlueConic for Enhanced Personalization and Data Privacy Compliance
- SalonInteractive Launches in Square App Marketplace to Provide eCommerce, Marketing & More to Beauty Professionals
- RacquetX Announces Miami Open Experience as Excitement Builds for Landmark 2024 Event
- Malta Closes Funding to Deploy Its Long-Duration Energy Storage System
- Dominating Business Intelligence: Informer Tops the BI & Analytics Survey for the Fourth Time
- IDC FutureScape: The Digital Business Era Has Arrived, Augmented by GenAI
- Mayor Wu Shares Boston's Winter Weather Preparations
- Labthink Introduces Cutting-Edge C406H: A Revolutionary Combination OTR and WVTR Tester
- You won't believe these amazing stories from our guest authors!
- St. Joseph's/Candler Fast Tracks Implementation of MEDITECH Expanse Ambulatory Across 100+ Providers
- Advcash adds instant Pix payments in Brazil
- Floris United Methodist Church announces first-ever mission trip for people with disabilities
- Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notes
- Sip Social Co. Partners With Omnify To Streamline User Experience Across Growing Operations
- City of Boston Celebrates Grand Opening of 250 Centre Street
- Fred Nassiri Relaunches "Love Sees No Colour"
- TKO Miller Advises Visu-Sewer on its Partnership With Fort Point Capital
- Vicinity Energy Steams Ahead to Sustainable Future with Arrival of 42MW Electric Boiler in Cambridge, Mass.
- Investing in Boston's Adult Learners: Adult Literacy Initiative